Kenton L. Longenecker

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Emily J. Faivre, Keith F. McDaniel, Daniel H. Albert et al. · Nature · 2020 · 404 citations

Life Sciences, Molecular Biology, Oncology +10

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

Christina K. Baumgartner, Hakimeh Ebrahimi-Nik, Arvin Iracheta‐Vellve et al. · Nature · 2023 · 174 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Three-dimensional Structure of Mammalian Casein Kinase I: Molecular Basis for Phosphate Recognition

Kenton L. Longenecker, Peter J. Roach, Thomas D. Hurley · Journal of Molecular Biology · 1996 · 132 citations

Life Sciences, Biochemistry, Molecular Biology +14

Protein crystallization by rational mutagenesis of surface residues: Lys to Ala mutations promote crystallization of RhoGDI

Kenton L. Longenecker, Sarah Garrard, Peter Sheffield et al. · Acta Crystallographica Section D Biological Crystallography · 2001 · 124 citations

Life Sciences, Biochemistry, Molecular Biology +13

Discovery of <i>N</i>-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1<i>H</i>-pyrrolo[2,3-<i>c</i>]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain

George S. Sheppard, Le Wang, Steven D. Fidanze et al. · Journal of Medicinal Chemistry · 2020 · 121 citations · Full text

Medicine, Oncology, Pharmacology +12